Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 3/2017

01-05-2017 | Author’s reply

Disease-free interval in metastatic breast cancer patients undergoing complete remission: implications of cross-sectional study design and biologic considerations about disease history

Authors: Giulia Galli, Anna Tessari, Serena Di Cosimo

Published in: Breast Cancer | Issue 3/2017

Login to get access

Excerpt

To the Editor …
Literature
1.
Galli G, Tessari A, Porcu L, Bregni G, Paolini B, Carcangiu ML, et al. Complete remission in metastatic breast cancer: expecting the unexpected—results of a cross-sectional study. Breast Cancer. 2017. doi:10.​1007/​s12282-017-0751-6 [Epub ahead of print].
2.
Altundag K. Does longer disease free interval affect the complete remission in metastatic breast cancer? Breast Cancer. 2017;16:1–1 [Epub ahead of print].
3.
Hudson JI, Pope HG Jr, Glynn RJ. The cross-sectional cohort study: an underutilized design. Epidemiology. 2005;16(3):355–9.CrossRefPubMed
4.
Loibl S, von Minckwitz G, Untch M, Denkert C, German Breast Group C. Predictive factors for response to neoadjuvant therapy in breast cancer. Oncol Res Treat. 2014;37(10):563–8.CrossRefPubMed
Metadata
Title
Disease-free interval in metastatic breast cancer patients undergoing complete remission: implications of cross-sectional study design and biologic considerations about disease history
Authors
Giulia Galli
Anna Tessari
Serena Di Cosimo
Publication date
01-05-2017
Publisher
Springer Japan
Published in
Breast Cancer / Issue 3/2017
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-017-0766-z

Other articles of this Issue 3/2017

Breast Cancer 3/2017 Go to the issue

Erratum

Erratum to: Genetic variants of ESR1 and SGSM3 are associated with the susceptibility of breast cancer in the Chinese population

Original Article

Feasibility and potential limitations of abbreviated breast MRI: an observer study using an enriched cohort

Original Article

Long-term prospective assessment of shoulder function after breast reconstruction involving a latissimus dorsi muscle flap transfer and postoperative radiotherapy

Original Article

Mammographic extent of microcalcifications and oestrogen receptor expression affect preoperative breast carcinoma in situ size estimation

Original Article

Med19 promotes breast cancer cell proliferation by regulating CBFA2T3/HEB expression

Erratum

Erratum to: Breast reconstruction using free medial circumflex femoral artery perforator flaps: intraoperative anatomic study and clinical results
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits